Top London Biotech Companies (140)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
At Eucalyptus, we run a trusted group of digital healthcare clinics on our telehealth platform including Pilot (men’s health), Kin (fertility), Software (dermatology) and Juniper (weight loss and menopause). Our mission is to bring high-touch, high-quality healthcare to patients around the world by empowering practitioners with technology. Since 2019, we’ve facilitated over one million consultations across Australia, the UK and Germany. With every consult, we’re breaking down boundaries to better health by providing better access to care, stigma-free experiences, and continuous support. Our commitment to providing better patient experiences is matched by our stellar record of patient safety. To learn more about Eucalyptus, visit our website
At Convergence, our mission is to build a future of abundance for all of humanity. We are developing the first generation of truly general agents that can pick up any skill by actively working and learning from experience.
The Crick is a distinctive biomedical research institute. We’re committed to advancing, promoting, and sharing understanding of human health and disease. We do that by attracting talented and ambitious people from all disciplines and backgrounds and giving them the support and freedom they need to succeed. Inside the Crick, you’ll discover scientists working to stretch the very limits of what we know about how life works. Their research holds the key to answering fundamental questions about human health and disease. Our bold and innovative research projects bring together scientists and technicians from all disciplines in the pursuit of discovery without boundaries. With the support of our partners, we’re bridging the gap between discovery and application to help change lives for the better. And through our dynamic structure, we’re able to develop the science leaders of tomorrow. That’s our bold idea, tell us yours. Cover image taken at the Crick by Thomas Angus, Imperial College London
Based in London, Hoxton Farms is creating a deliciously fatty future. We craft cruelty-free, sustainable fats to combine with plant protein for delicious meat alternatives
Mytos automates one of the last highly manual processes in biotech - growing human cells. Our products help teams in drug development and cell therapy save time while increasing the reproducibility of their data. Mytos is backed by a fleet of leading investors including YCombinator. Our team is made up of brilliant engineers from Dyson, Formlabs and Cambridge Consultants and driven scientists who have worked in top labs including at Imperial College, University of Cambridge and UCL. We're hiring now- visit our website to see open positions
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
.png)
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family story and gain a new level of understanding about their lives. For 40 years, we’ve built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing their story.
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world. For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?” Social Media Guidelines: https://gilead.inc/3t1m7d5
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population
Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.
Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease
Emm is developing the next generation of bio-wearables for better healthcare
We’re a team made up of healthcare workers who’ve lived the struggles of temporary staffing. So we’re here to transform the way it’s managed once and for all, by unleashing the power of flexible working to solve the global healthcare workforce crisis. How do we do it? We combine our industry-leading technology with our extensive specialist expertise - to bring an entirely tailored service to each healthcare organisation and solve their unique challenges for good. With Patchwork, we go beyond simply achieving the obvious requirements of surging staff bank growth and fill rates, slashing agency spend, increasing patient safety and saving time. But what truly transforms our partner organisations is our first-hand healthcare experience and expertise, our genuine passion and tireless effort to create real change for the future. Let’s together unleash the power of flexible working
Hurdle's mission is clear: democratize access to biology for companies and consumers by creating cutting-edge bio-infrastructure. Harnessing deep expertise, our tech-driven platform integrates easily with any business system. With its modular and end-to-end capabilities, Hurdle ensures biology data is not only accessible but also actionable, breaking down the traditional barriers. We're more than just a platform; we're catalysts for change. Through the profound power of biology, we aim to propel businesses and the world into a brighter, more informed future. Whether your goal is boosting revenue, expanding consumer reach, or broadening horizons, Hurdle paves the way with solutions tailored to every challenge. Join us in our journey to unlock biology's untapped potential, empowering organizations with the deep insights they need to thrive. Discover the Hurdle difference at hurdle.bio. Proudly a brand under Chronomics Ltd. Inc
At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
QIO Technologies is a sustainability tech company delivering Industrial IoT AI software products supporting energy-intensive and asset-heavy Industrial, Data Center and Telecom companies to reduce greenhouse gas emissions, improve energy efficiency, and accelerate operational sustainability. QiO developed its Foresight Sustainability Suite™ in response to the difficulties faced by industry in leveraging large, disparate sources of operational data to reduce GHG emissions and improve operational efficiency. By applying its AI optimisation technology in sectors ranging from automotive, steel, glass, cement, oil & gas, data centers and telecoms, Foresight Sustainability Suite™ has delivered up to 20% savings on energy and maintenance costs and reduced GHG emissions by up to 10%. QiO’s newest product, Foresight Optima DC+™, was developed in partnership with Intel to meet the needs of energy-intensive data centers. Foresight Optima DC+™ has delivered energy savings and emissions reductions of up to 50% in data centers worldwide by analysing energy consumption and making real-time adjustments to individual servers. QiO’s Foresight Sustainability Suite™ operates by collecting data from industrial assets ranging from kilns, furnaces, boilers and compressors to cooling systems and data center servers. Using AI, Foresight Sustainability Suite™ identifies and implements real-time actions that optimise energy efficiency and resource use, helping customers make rapid reductions in GHG emissions, energy use, production costs and waste. With businesses under pressure to meet international sustainability reporting standards, Foresight Sustainability Suite™ also automates real-time ESG reporting, enabling every customer to track and report Scope 1 and Scope 2 emissions.
Work Your Passion. Live Your Purpose.
